Published online before print September 13, 2007, doi: 10.1161/CIRCRESAHA.107.154401
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 American Heart Association, Inc.
Integrative Physiology |
Increased Atherosclerotic Lesion Calcification in a Novel Mouse Model Combining Insulin Resistance, Hyperglycemia, and Hypercholesterolemia
From the Department of Biotechnology and Molecular Medicine (S.E.H., P.L., I.K., H.L., S.-K.H., S.Y.-H.), A.I. Virtanen Institute, University of Kuopio, Finland; the Center of Animal Biotechnology and Gene Therapy (F.B.), Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; the Department of Biochemistry and Molecular Biology (F.B.), School of Veterinary Medicine, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; and the Departments of Medicine (M.L., S.Y.-H.) and the Gene Therapy Unit (S.Y.-H.), Kuopio University Hospital, Kuopio, Finland.
Correspondence to Seppo Ylä-Herttuala, MD, PhD, FESC, Professor of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, PO Box 1627, FI-70211, Kuopio, Finland. E-mail Seppo.Ylaherttuala{at}uku.fi
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
No mouse model is currently available where the induction of type 2 diabetes on an atherosclerotic background could be achieved without significant concomitant changes in plasma lipid levels. We crossbred 2 genetically modified mouse strains to achieve a model expressing both atherosclerosis and characteristics of type 2 diabetes. For atherosclerotic background we used low-density lipoprotein receptor–deficient mice synthetizing only apolipoprotein B100 (LDLR–/– ApoB100/100). Diabetic background was obtained from transgenic mice overexpressing insulin-like growth factor-II (IGF-II) in pancreatic beta cells. Thorough phenotypic characterization was performed in 6- and 15-month-old mice on both normal and high-fat Western diet. Results indicated that IGF-II transgenic LDLR–/–ApoB100/100 mice demonstrated insulin resistance, hyperglycemia, and mild hyperinsulinemia compared with hypercholesterolemic LDLR–/–ApoB100/100 controls. In addition, old IGF-II/LDLR–/–ApoB100/100 mice displayed significantly increased lesion calcification, which was more related to insulin resistance than glucose levels, and significantly higher baseline expression in aorta of several genes related to calcification and inflammation. Lipid levels of IGF-II/LDLR–/–ApoB100/100 mice did not differ from LDLR–/–ApoB100/100 controls at any time. In conclusion, type 2 diabetic factors induce increased calcification and lesion progression without any lipid changes in a new mouse model of diabetic macroangiopathy.
Key Words: type 2 diabetes • atherosclerosis • insulin resistance • mouse model • hypercholesterolemia
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Type 2 diabetes is a heterogenous disorder characterized by peripheral insulin resistance (IR) and ß-cell failure. Individuals with IR and a resulting impaired glucose tolerance as well as with overt type 2 diabetes have an increased predisposition to atherosclerosis and related cardiovascular diseases,1 which are also the major causes of mortality in these patients.2
It has remained unclear whether induction of type 2 diabetes in atherosclerosis-prone mice can be attained in the absence of altered lipid levels.3 In humans, diabetes itself does not generally lead to marked elevations in total cholesterol. However, in most animal models, induction of diabetes causes major concomitant changes in lipid values.3 Thus, it has been very difficult to differentiate the effects of diabetic factors from those of hyperlipidemia, especially in mice where hypercholesterolemia is clearly the most essential factor for the development of atherosclerotic lesions.3
The low-density lipoprotein receptor–deficient mice able to synthesize only apolipoprotein B100 (LDLR–/–ApoB100/100) represent a model of hypercholesterolemia with elevated levels of LDL cholesterol and expression of only apolipoprotein B100. This leads to accelerated atherogenesis4 and a lipid profile, which resembles the type commonly found in human hypercholesterolemia and atherosclerosis5 better than any other mouse model currently available. Therefore, the LDLR–/–ApoB100/100 mice are well suited to experimental atherosclerosis studies because they better resemble human situation than, eg, the apolipoprotein E–knockout mice (ApoE–/–),6,7 which have a very different remnant-like lipoprotein pattern compared with humans and lack all functions of apolipoprotein E on cholesterol homeostasis, cellular cholesterol efflux and inflammatory responses.8
We cross-bred the atherogenic LDLR–/–ApoB100/100 mice with transgenic mice in which type 2 diabetes is caused by overexpressing insulin-like growth factor-II (IGF-II) in pancreatic beta (ß) cells.9 A model was generated which manifests characteristics of type 2 diabetes with no major changes in the plasma lipoprotein fractions while still showing worsening of the macrovascular lesion phenotype.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Mice deficient of LDL receptor and expressing only apolipoprotein B100 (LDLR–/–ApoB100/100)4 in C57BL/6x129/SvJae background (The Jackson Laboratory, Bar Harbor, Me) were crossbred with C57BL6/SJL mice overexpressing IGF-II in pancreatic ß-cells9 for 10 generations. IGF-II negative LDLR–/–ApoB100/100 littermates served as controls. Both 6- and 15-month-old mice were examined either so that they were fed with a normal chow diet (R36, Lactamin) for the whole time or a high fat, Western diet (TD 88173, Harlan Teklad: 42% of calories from fat and 0.15% from cholesterol, no sodium cholate) for the last 3 months. Both female and male mice were used in this study, and the study groups contained equal numbers of both sexes. Experiments were approved by the Experimental Animal Committee of the University of Kuopio.
For further details and other methods, see Materials and Methods data supplement available at http://circres.ahajournals.org.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Insulin Resistance and Hyperglycemia in the IGF-II/LDLR–/–ApoB100/100 Mice
Intraperitoneal glucose (GTT) and insulin tolerance tests (ITT) were performed to investigate glucose intolerance and insulin resistance. In the GTT a sustained elevation of blood glucose level was observed in IGF-II/LDLR–/–ApoB100/100 mice. This finding was evident on both normal (Figure 1B) and Western diet (Figure 1A), which suggests that the IGF-II/LDLR–/–ApoB100/100 mice are glucose-intolerant independently of the diet. To examine insulin secretion in response to intraperitoneal glucose injection during the GTT, plasma insulin levels were determined at different time points in the group on Western diet (Figure 1C). In contrast to LDLR–/–ApoB100/100 controls, despite being hyperinsulinemic in the beginning, an absent acute first phase insulin response after glucose stimulation was observed in the IGF-II/LDLR–/– ApoB100/100 mice and their insulin levels remained almost unchanged from 60 to 120 minutes. Furthermore, in the ITT a significantly reduced insulin sensitivity after insulin administration was observed in the IGF-II/LDLR–/–ApoB100/100 group on normal diet (Figure 1D).
|
Diabetic Factors Do Not Cause Changes in Lipid Levels but Raise the Basal Osteoprotegerin Level
Metabolic parameters are presented in Table 1. Glucose levels of 6-month-old IGF-II/LDLR–/–ApoB100/100 mice were significantly elevated on normal diet both in fed and fasted states. The effect of Western diet on fasting glucose levels was larger in the group of IGF-II/LDLR–/–ApoB100/100 mice: glucose levels were notably higher compared with LDLR–/– ApoB100/100 controls (7.5±2.1 versus 4.7±1.5 mmol/L, P<0.05) and 16% of the IGF-II/LDLR–/–ApoB100/100 mice demonstrated fasting glucose values over 10 mmol/L versus none of the LDLR–/–ApoB100/100 mice. Similar findings were also seen in 15-month-old animals on Western diet, although differences on normal diet had disappeared. On normal diet, plasma insulin levels of fed IGF-II/LDLR–/–ApoB100/100 mice were twice as high as those of the LDLR–/–ApoB100/100 controls (2.1±0.5 versus 1.0±0.1 ng/mL, respectively, P<0.05) but the difference was lost in fasting state. An opposite trend was seen on Western diet, where the fasting insulin levels in the IGF-II/LDLR–/–ApoB100/100 group were 2-fold higher compared with the LDLR–/–ApoB100/100 controls (3.0±0.5 versus 1.5±0.3 ng/mL, P<0.05). Except for the trend that IGF-II/LDLR–/–ApoB100/100 females seemed to gain more weight than did the control females, no significant differences in body weights were detected neither on normal nor Western diet and therefore the elevation of insulin levels in IGF-II/LDLR–/–ApoB100/100 mice cannot be explained by weight change. Combination of mild hyperglycemia with elevated insulin levels in the IGF-II/LDLR–/–ApoB100/100 mice indicates insulin resistance, leading to even more severe phenotype after 3 months of Western diet.
|
Severe hypercholesterolemia developed on Western diet both in IGF-II/LDLR–/–ApoB100/100 and LDLR–/–ApoB100/100 mice without any differences between the groups and sexes (Table 1). Similar trend was observed in fasting free fatty acids levels (FFA), whereas no changes were present in fasting triglycerides. Thus, diabetic factors present in the IGF-II/LDLR–/–ApoB100/100 mouse did not cause any detectable changes in the lipid metabolism. Interestingly, 15-month-old IGF-II/LDLR–/–ApoB100/100 mice had a significantly higher plasma osteoprotegerin (OPG) level than LDLR–/–ApoB100/100 controls on normal diet. In hypercholesterolemic state on Western diet the OPG level was equally augmented in both groups. However, despite the general elevation, IGF-II/LDLR–/–ApoB100/100 females still displayed higher OPG levels than did the control females (P=0.019, data not shown).
Overall Lesion Development Is Not Affected by Diabetic Factors
Atherosclerosis was quantified both en face from the whole aorta and from serial cross-sections from the aortic sinus level. In the en face analysis the distribution of macroscopic lesions in 6-month-old mice was similar in both groups and they occurred at typical sites for LDLR–/– mice exposed to prolonged hypercholesterolemia.10 There were no differences in the overall area of macroscopic lesions between 6-month-old IGF-II/LDLR–/–ApoB100/100 mice and LDLR–/–ApoB100/100 controls neither on normal (14.0±3.6% versus 14.3±5.2%, respectively) nor on Western diet (14.4±3.8% versus 16.6±3.5%, respectively; Figure 2A). Hence, the mild hyperglycemia observed in the IGF-II/LDLR–/–ApoB100/100 mice did not have a direct effect on the lesion area, and no significant correlation was seen between fasting glucose levels and lesion areas (Figure 2B). However, on Western diet there was a strong correlation between the extent of lesions and fed state insulin levels in IGF-II/LDLR–/–ApoB100/100 mice (r=0.74, P<0.05), which was not detectable in LDLR–/–ApoB100/100 controls (r=0.56, NS; Figure 2C).
|
Although the overall en face lesion area of 6-month-old mice was not considerably affected by Western diet, thickness of the lesions increased significantly in both groups after three months of Western diet as seen in the cross-sectional analysis. Compared with mice on normal diet, lesion size increased by 5.1-fold in IGF-II/LDLR–/–ApoB100/100 mice (from 9.6±6.0% to 49.2±5.2%, P<0.0001) and by 2.9-fold in LDLR–/–ApoB100/100 controls (from 17.3±9.2% to 49.5±8.9%, P<0.0001; Figure 2D). Aging also enhanced lesion development: compared with 6-month-old animals the average cross-sectional lesion area was more than doubled in 15-month-old mice on normal diet (35.6±6.9% in IGF-II/LDLR–/–ApoB100/100 mice and 39.5±8.6% in controls, P<0.01 in both groups; Figure 2E). Nevertheless, Western diet further increased the lesion size also in older animals with cross-sectional areas of 52.2±9.2% in IGF-II/LDLR–/– ApoB100/100 mice (P<0.01) and 56.8±8.0% in the LDLR–/– ApoB100/100 group (P<0.001; Figure 2E). However, no differences in the final lesion areas were found between the groups on normal or Western diet.
Increased Calcification and Accelerated Lesion Progression in IGF-II/LDLR–/–ApoB100/100 Mice
To investigate the role of aging and diet on the development of lesions, composition of the lesions was examined from aortic cross-sections from both 6- and 15-month-old mice. In younger animals on normal diet the lesions mainly consisted of macrophage-derived foam cells (Figure 3A and 3B). On Western diet (Figure 3C and 3D) the amount of cholesterol crystals was increased over 2-fold in both groups and calcification was detected in 40% of the IGF-II/LDLR–/–ApoB100/100 mice, and in 17% of the LDLR–/–ApoB100/100 controls (data not shown). In general, the lesion phenotype of 6-month-old IGF-II/LDLR–/–ApoB100/100 mice was typical for hypercholesterolemic animals without major changes compared with the LDLR–/–ApoB100/100 background, except for a slightly higher occurrence of calcification. In 15-month-old mice no calcification was found on normal diet, even though the lesion sizes were comparable to younger mice on Western diet (Figure 3E and 3F). When old mice on Western diet were examined, the IGF-II/LDLR–/–ApoB100/100 mice revealed significantly more calcification than LDLR–/–ApoB100/100 controls (12.0±3.5% versus 2.9±1.6% from the plaque area, P<0.001) (Figure 4A–C). This finding was especially pronounced in female mice as 83% of the IGF-II/LDLR–/–ApoB100/100 mice and only 43% of the control females displayed calcification. When the calcified areas and cholesterol clefts were combined to assess the total size of the necrotic core, IGF-II/LDLR–/–ApoB100/100 mice demonstrated significantly higher percentages than LDLR–/–ApoB100/100 controls (38.0±16.0% versus 16.6±13.0%, P<0.05; Figure 4D). In addition, the IGF-II/LDLR–/–ApoB100/100 mice also manifested a more advanced lesion phenotype with less organized structure and focal thinning of the fibromuscular cap (Figure 3G and 3H).
|
|
Plaque calcification did not correlate significantly with fasting glucose levels (Figure 4E). However, plotting calcification against the incremental glucose areas under the curve (AUC) in a GTT suggested a connection between these parametres (Figure 4F). Hence, it seems that in this model the factors stimulating intimal calcification are more evidently related to insulin resistance than to hyperglycemia.
Mechanisms of Increased Calcification
To study the mechanims behind increased calcification, we first examined the expression of different molecules in the lesions by immunohistochemical methods in 6- and 15-month-old mice on both diets (Table 2). We observed intensity changes in the stainings attributed to aging or diet without any significant differences between the IGF-II/LDLR–/–ApoB100/100 mice and LDLR–/–ApoB100/100 controls. In the assessment of angiogenic markers in the lesions only a weak VEGF signal was detected in both groups, mostly localizing in macrophages and also sparsely in the medial smooth muscle cells (Figure 5A and 5B). These cell types, together with the endothelium, demonstrated an intense RAGE immunoreactivity as well (Figure 5C and 5D). Groups also showed equal lesional macrophage contents (data not shown) and similar expression patterns with inflammatory markers such as VCAM-1 (Figure 5E and 5F), ICAM-1 (Figure 5G and 5H), and Nf
B (Figure 5I and 5J). No quantifiable differences in the expression of eNOS (Figure 5K and 5L), OPN (Figure 5M and 5N), oxidized LDL, neovascularization, proliferation or apoptosis (data not shown) in the lesions could be detected by immunohistochemistry.
|
|
We next examined the expression levels of selected genes in tissue samples of intact aorta and lesions from 15-month-old mice on Western diet with quantitative real-time RT-PCR. Results revealed that the baseline expression of genes related to calcification (OPN, ALP-2 and BMP-2, Figure 6A through 6C) and inflammation (MCP-1, Figure 6E) as well as scavenger receptor CD36 (Figure 6D) were higher in IGF-II/LDLR–/–ApoB100/100 mice than in normal aortas of hypercholesterolemic LDLR–/–ApoB100/100 controls. No statistical differences were found between the groups in the expression of Bax (Figure 6G) or IL-6 (Figure 6F), although there was a trend toward a higher IL-6 expression in lesions of the IGF-II/LDLR–/–ApoB100/100 mice and the change seen in lesional Bax expression was similar to that found in human studies of carotid lesions.11
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Studying diabetic angiopathy and cardiovascular complications related to type 2 diabetes in vivo has been difficult because of the lack of good animal models. In the present study we examined the effects of insulin resistance and hyperglycemia on the atherogenic background LDLR–/– ApoB100/100 demonstrating an atherogenic lipoprotein profile resembling that of humans. By cross-breeding these mice with type 2 diabetic IGF-II transgenic mice, we achieved a promising atherosclerosis model expressing type 2 diabetic features with no additional changes in hyperlipidemia but, nevertheless, worsening of the lesion phenotype.
Clinical trials12 show that the treatment of hyperglycemia in type 2 diabetes does not reduce macrovascular complications. Therefore choosing an appropriate animal model for studies on the effects of diabetes on atherosclerosis is crucial. So far, attempts to generate mouse models for type 2 diabetes and atherosclerosis have usually been based either on feeding the atherosclerosis-prone LDLR–/– or ApoE–/– mice different diets or crossing them with models of obesity and type 2 diabetes, such as leptin-deficient (ob/ob) or leptin receptor–deficient (db/db) mice. However, the main difficulty with dietary induction of type 2 diabetes has been that the effects vary considerably depending on the mouse model and especially on the duration and composition of the diet.13–15 Generally, the changes in glucose metabolism have also been quite modest, thus resulting in a situation where severe hypercholesterolemia usually masks their possible contribution to the lesion development. This has been the case also for crossings with models of disturbed leptin metabolism, because parallel to glucose and insulin levels also total cholesterol is significantly increased in LDLR–/–ob/ob,16,17 ApoE–/– ob/ob17 and ApoE–/–db/db18,19 mice compared with the respective LDLR–/– or ApoE–/– controls. Therefore, the main driving force of lesion progression in these models is probably still increased cholesterol level, supported by the observations that no lesions developed when ob/ob mice were crossed with LDLR+/– mice having a markedly lower cholesterol level16 and that the plain diabetic IGF-II transgenic mice do not develop atherosclerotic lesions if cholesterol levels are low (Heinonen et al, unpublished observation). In our study the background models were chosen to avoid disturbances in the levels and functions of apolipoprotein E and leptin, because they both have important and complex roles in physiology. In addition, instead of using only relatively young animals, we examined also old mice to investigate the effects of diabetes on advanced lesions and to mimic physiological conditions of an average type 2 diabetes patient with cardiovascular complications.
In the present study both IGF-II/LDLR–/–ApoB100/100 mice and LDLR–/–ApoB100/100 controls developed atherosclerotic lesions covering about 15% of the total aortic area. This finding is in line with other studies performed with the LDLR–/–ApoB100/100 model.20,21 Hypercholesterolemia induced by Western diet clearly thickened the plaques in both groups and led to the development of more advanced lesions with macrophage infiltrates and large necrotic areas covered by a fibrous cap. Nevertheless, the observed association between en face lesion area and fed state insulin level in the IGF-II/LDLR–/–ApoB100/100 mice supports the proatherogenic effect of the prediabetic state. In addition, compared with the LDLR–/–ApoB100/100 controls, IGF-II/LDLR–/–ApoB100/100 mice on Western diet and especially in the group of old mice presented clearly less organized and more complex lesions with significantly increased calcification. Larger necrotic cores22,23 and increased calcification23 in coronary plaques have been reported also in type 2 diabetes patients with sudden coronary death. In fact, the presence of radiologically detectable calcification in peripheral arteries,24 coronaries, or abdominal aorta25 are all reported to be strong markers of future cardiovascular events in patients with type 2 diabetes. Our findings that the calcification was most profound in old animals is consistent with clinical studies, where age and duration of diabetes have remained as independent risk factors for coronary artery calcification in type 2 diabetics.26,27
There are several possible mechanisms which could cause increased calcification in type 2 diabetes. For example, AGE formation has been connected to vascular calcification.28 However, in our study aortic RAGE expression was equal in both groups and thus the AGE-RAGE interaction probably does not explain increased calcification. This is not surprising, because hypercholesterolemia makes the vasculature of also nondiabetic mice susceptible to oxidant stress, inflammation and generation of AGEs. In support of this notion, soluble RAGE administration has been reported to attenuate the lesion area and complexity also in normoglycemic hypercholesterolemic mice.29 RAGE activation has also been suggested to stimulate VEGF expression in atherosclerotic plaques.30,31 Thus, uniform RAGE expression between the groups might account for the similarity of VEGF expression and the subsequent lack of differences in intraplaque angiogenesis as well. The presence of several other molecules in atherosclerotic lesions was also examined using immunohistochemical methods. Moderate expression of eNOS and NfB was detected in lesions of old IGF-II/LDLR–/–ApoB100/100 and LDLR–/–ApoB100/100 mice on Western diet, whereas intense stainings for VCAM-1, ICAM-1, and OPN were found in lesions of both diabetic and nondiabetic mice. However, none of these findings were able to explain increased calcification of lesions in the diabetic IGF-II/LDLR–/–ApoB100/100 mice, probably because the potential underlying differences are beyond the sensitivity of immunohistochemistry. When quantitative RT-PCR was used for the analysis of candidate gene expression in normal aortas and atherosclerotic lesions we found much higher baseline expression levels of all calcification-related genes (OPN, ALP-2 and BMP-2) in normal aortas of IGF-II/LDLR–/–ApoB100/100 mice. The role of these factors in diabetic vascular calcification has been widely recognized.32–34 The same profile was observed in scavenger receptor CD36 expression which is in line with human studies35 and suggests a proatherogenic mechanism through increased macrophage uptake of LDL. Increased expression levels of MCP-1 and IL-6 suggest a trend toward a more inflammatory environment in the lesions of IGF-II/LDLR–/–ApoB100/100 mice. When also higher plasma OPG levels of the IGF-II/LDLR–/–ApoB100/100 mice are taken into account, it seems likely that no currently known single factor is solely responsible for the increased calcification but accelerated lesion progression is rather a net result of several factors upregulated in the diabetic aorta.
In conclusion, the IGF-II/LDLR–/–ApoB100/100 model generated in this study demonstrates significantly increased atherosclerotic calcification and complexity of atherosclerotic lesions in older animals, and thus represents a very promising new model for studies of macrovascular complications in type 2 diabetes.
|
Acknowledgments |
|---|
The authors thank Riina Kylätie for excellent technical assistance and Marja Poikolainen for preparing the manuscript.
Sources of Funding
This study was supported by grants from the Finnish Academy, Sigrid Juselius Foundation, the Finnish Foundation for Cardiovascular Research, the Finnish Cultural Foundation, Aarne Koskelo Foundation, the Kuopio University Foundation, Clinigene (grant LSHB-CT-2006-018933), EVGN (European Vascular Genomics Network, grant LSHM-CT-2003-503254), and the European Union (grant LSHM-CT-2004-512013).
Disclosures
None.
|
Footnotes |
|---|
Original received April 24, 2007; revision received August 23, 2007; accepted September 5, 2007.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987; 3: 463–524.[Medline] [Order article via Infotrieve]
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229–234.
3. Goldberg IJ, Dansky HM. Diabetic vascular disease: an experimental objective. Arterioscler Thromb Vasc Biol. 2006; 26: 1693–1701.
4. Veniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice. J Clin Invest. 1998; 102: 1559–1568.[Medline] [Order article via Infotrieve]
5. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Diseases. New York: McGraw-Hill; 1989: 1215–1250.
6. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A. 1992; 89: 4471–4475.
7. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992; 71: 343–353.[CrossRef][Medline] [Order article via Infotrieve]
8. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol. 2000; 11: 243–251.[CrossRef][Medline] [Order article via Infotrieve]
9. Devedjian JC, George M, Casellas A, Pujol A, Visa J, Pelegrin M, Gros L, Bosch F. Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes. J Clin Invest. 2000; 105: 731–740.[Medline] [Order article via Infotrieve]
10. Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 1995; 15: 1569–1576.
11. Martinet W, Schrijvers DM, De Meyer GR, Thielemans J, Knaapen MW, Herman AG, Kockx MM. Gene expression profiling of apoptosis-related genes in human atherosclerosis: upregulation of death-associated protein kinase. Arterioscler Thromb Vasc Biol. 2002; 22: 2023–2029.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998/9/12; 352: 837–853.
13. Merat S, Casanada F, Sutphin M, Palinski W, Reaven PD. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler Thromb Vasc Biol. 1999; 19: 1223–1230.
14. Schreyer SA, Vick C, Lystig TC, Mystkowski P, LeBoeuf RC. LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am J Physiol Endocrinol Metab. 2002; 282: E207–E214.
15. Wu L, Vikramadithyan R, Yu S, Pau C, Hu Y, Goldberg IJ, Dansky HM. Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis. J Lipid Res. 2006; 47: 2215–2222.
16. Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N, Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Okazaki H, Ohashi K, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai R, Ishibashi S, Yamada N. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem. 2001; 276: 37402–37408.
17. Gruen ML, Saraswathi V, Nuotio-Antar AM, Plummer MR, Coenen KR, Hasty AH. Plasma insulin levels predict atherosclerotic lesion burden in obese hyperlipidemic mice. Atherosclerosis. 2006; 186: 54–64.[CrossRef][Medline] [Order article via Infotrieve]
18. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis. 2006; 185: 70–77.[CrossRef][Medline] [Order article via Infotrieve]
19. Wu KK, Wu TJ, Chin J, Mitnaul LJ, Hernandez M, Cai TQ, Ren N, Waters MG, Wright SD, Cheng K. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis. 2005; 181: 251–259.[CrossRef][Medline] [Order article via Infotrieve]
20. Leppanen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U, Alitalo K, Yla-Herttuala S. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation. 2005; 112: 1347–1352.
21. Veniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, Hellerstein MK, Rudel LL, Walzem RL, Young SG. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest. 2000; 106: 1501–1510.[Medline] [Order article via Infotrieve]
22. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000; 102: 2180–2184.
23. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004; 24: 1266–1271.
24. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996; 16: 978–983.
25. Reaven PD, Sacks J, Investigators for the VADT. Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes. Diabetologia. 2005; 48: 379–385.[CrossRef][Medline] [Order article via Infotrieve]
26. Godsland IF, Elkeles RS, Feher MD, Nugara F, Rubens MB, Richmond W, Khan M, Donovan J, Anyaoku V, Flather MD, for the PREDICT Study Group. Coronary calcification, homocysteine, C-reactive protein and the metabolic syndrome in Type 2 diabetes: the Prospective Evaluation of Diabetic Ischemic Heart Disease by Coronary Tomography (PREDICT) Study. Diabet Med. 2006; 23: 1192–1200.[CrossRef][Medline] [Order article via Infotrieve]
27. Wagenknecht LE, Bowden DW, Carr JJ, Langefeld CD, Freedman BI, Rich SS. Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes. 2001; 50: 861–866.
28. Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int. 2006; 70: 218–224.[CrossRef][Medline] [Order article via Infotrieve]
29. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002; 106: 2827–2835.
30. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 2002; 16: 1928–1930.
31. Roy H, Bhardwaj S, Babu M, Kokina I, Uotila S, Ahtialansaari T, Laitinen T, Hakumaki J, Laakso M, Herzig K, Yla-Herttuala S. VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-{kappa}B, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits. FASEB J. 2006; 20: 2159–2161.
32. Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab. 2004; 286: E686–96.
33. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004; 24: 1161–1170.
34. Fadini GP, Pauletto P, Avogaro A, Rattazzi M. The good and the bad in the link between insulin resistance and vascular calcification. Atherosclerosis. 2007; 193: 241–244.[CrossRef][Medline] [Order article via Infotrieve]
35. Sampson MJ, Davies IR, Braschi S, Ivory K, Hughes DA. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. Atherosclerosis. 2003; 167: 129–134.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  I. Laitinen, A. Saraste, E. Weidl, T. Poethko, A. W. Weber, S. G. Nekolla, P. Leppanen, S. Yla-Herttuala, G. Holzlwimmer, A. Walch, et al. Evaluation of {alpha}v{beta}3 Integrin-Targeted Positron Emission Tomography Tracer 18F-Galacto-RGD for Imaging of Vascular Inflammation in Atherosclerotic Mice Circ Cardiovasc Imaging, July 1, 2009; 2(4): 331 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Demer and Y. Tintut Vascular Calcification: Pathobiology of a Multifaceted Disease Circulation, June 3, 2008; 117(22): 2938 - 2948. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||